Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (NCT03972488)
A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
🩺 Plain-English Summary (8th-Grade Level)
The aim of NETTER-2 was to determine if Lutathera in combination with long-acting octreotide prolongs progression free survival (PFS) in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients with high proliferation rate tumors (G2 and G3), when given as a first line treatment compared to treatment with high dose (60 mg) long-acting octreotide. Somatostatin analog (SSA) naive patients were eligible, as well as patients previously treated with SSAs in the absence of progression.
Who can join: Review the eligibility criteria below.
Location: Yale Cancer Center — New Haven, Connecticut
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (40 Sites)
Showing the first 25 of 40 sites.
- Yale Cancer Center — New Haven, Connecticut
- USF - H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
- University of Iowa Hospitals and Clinics - Oncology — Iowa City, Iowa
- University of Kentucky UK Markey Cancer Center — Lexington, Kentucky
- Mayo Clinic - Oncology — Rochester, Minnesota
- MD Anderson Cancer Center — Houston, Texas
- London Health Sciences Centre, University of Western Ontario - Oncology — London,
- Centre Hospitalier Universitaire de Quebec — Québec,
- Sunnybrook Health Sciences Centre — Toronto,
- BC Cancer Agency — Vancouver,
- CHU Paris Nord-Val de Seine — Clichy,
- Hospices Civils de Lyon (HCL) - Hopital Edouard Herriot — Lyon,
- Institut du Cancer de Montpellier - Oncology — Montpellier,
- CHU-Hôtel Dieu Service de Médecine Nucléaire — Nantes,
- Institut Gustave Roussy — Villejuif,
- Universitätsklinikum Erlangen — Erlangen,
- Universitätsklinikum Essen - Klinik für Nuklearmedizin — Essen,
- A.O.di Bologna Policl.S.Orsola — Bologna,
- University of Genova - Oncology — Genova,
- Istituto Oncologico Romagnolo — Meldola,
- Fondazione Irccs Istituto Nazionale Tumori — Milan,
- Ieo, Irccs — Milan,
- IRCCS fondazione Pascale - Oncology — Naples,
- Arcispedale Santa Maria Nuova, Reggio Emilia - Oncology — Reggio Emilia,
- Azienda Ospedaliera Sant'Andrea - Università La Sapienza U.O.C. Mal App. Digerente e - Oncology — Roma,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Gastro-enteropancreatic Neuroendocrine Tumor
Explore by condition: All Gastro-enteropancreatic Neuroendocrine Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.